![]() One notable example is Candriam S.C.A., which recently acquired a new stake in 4D Molecular Therapeutics worth approximately $3,718,000.Īnother reason why investors remain bullish on 4D Molecular Therapeutics is due to its innovative approach to gene therapy development. These numbers indicate that 4D Molecular Therapeutics struggled in Q1 but should not be seen as indicative of its long-term potential.ĭespite these challenges, institutional investors and hedge funds continue to invest in 4D Molecular Therapeutics because they recognize the immense potential and long-term value that this company can bring to their portfolios. The company also reported an EPS of ($0.84), missing the consensus estimate of ($0.75) by ($0.09). Recently, 4D Molecular Therapeutics (NASDAQ: FDMT) announced its Q1 earnings results on Wednesday, March 15th.Īccording to the report, the company’s revenue for the quarter was $1.25 million, which was lower than consensus estimates of $4.97 million. One such company is 4D Molecular Therapeutics, a clinical stage biopharmaceutical company committed to developing gene therapy products for serious genetic diseases. Within this industry, there are some companies that stand out from the rest. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.The biotech industry is one of the most exciting sectors in the stock market. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 35% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. ![]() ![]() The current consensus EPS estimate is -$0.74 on $3 million in revenues for the coming quarter and -$3.08 on $15 million in revenues for the current fiscal year. ![]() It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. So, the shares are expected to perform in line with the market in the near future. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for 4D Molecular Therapeutics, Inc. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |